2012;96:130–9.PubMedCrossRef 3. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31:607–17.PubMedCrossRef 4. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001;12:2131–8.PubMed 5. Mathew S, Tustison KS, Sugatani T, Chaudhary
LR, Rifas L, Hruska KA. The mechanism of PI3K Inhibitor Library phosphorus as a cardiovascular risk factor in CKD. J Am Soc Nephrol. 2008;19:1092–105.PubMedCrossRef 6. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2009;(113):S1–130. 7. Lumlertgul D, Burke TJ, Gillum DM, Alfrey AC, Harris DC, Hammond WS, et al. Phosphate depletion arrests progression of chronic renal failure independent of protein intake. Kidney Int. 1986;29:658–66.PubMedCrossRef 8. Haut LL, Alfrey AC, 4EGI-1 Guggenheim S, Buddington B, Schrier N. Renal toxicity of phosphate in rats. Kidney Int. 1980;17:722–31.PubMedCrossRef 9. Hsu CH. Are we mismanaging calcium and phosphate metabolism in renal failure? Am J Kidney Dis. 1997;29:641–9.PubMedCrossRef 10. Ramirez JA, Emmett
M, White MG, Fathi N, Santa Ana CA, Morawski SG, et al. The absorption of dietary phosphorus and calcium in hemodialysis patients. Kidney Int. 1986;30:753–9.PubMedCrossRef 11. Tonelli M, Pannu N, buy Dinaciclib Manns B. Oral phosphate binders in patients with kidney failure. N Engl J Med. 2010;362:1312–24.PubMedCrossRef 12. Coladonato JA. Control of hyperphosphatemia among patients with ESRD. J Am Soc Nephrol. 2005;16(Suppl 2):S107–14.PubMedCrossRef 13. Hutchison AJ, Smith CP, Brenchley PEC. Pharmacology, efficacy and safety of oral phosphate binders. Nat Rev Nephrol. 2011;7:578–89.PubMedCrossRef 4��8C 14. Bellasi A, Kooienga L, Block GA. Phosphate
binders: new products and challenges. Hemodial Int. 2006;10:225–34.PubMedCrossRef 15. Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol. 2012;23:1407–15.PubMedCrossRef 16. Di Iorio B, Bellasi A, Russo D, INDEPENDENT Study Investigators. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol. 2012;7:487–93.PubMedCrossRef 17. Chase P, Dupre J, Mahon J, Ehrlich R, Gale E, Kolb H, et al. Nicotinamide and prevention of diabetes. Lancet. 1992;339:1051–2.PubMedCrossRef 18. Gale EAM, Bingley PJ, Emmett CL, Collier T. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet. 2004;363:925–31.PubMedCrossRef 19. Denekamp J, Fowler JF.